化疗引起的神经性疼痛 (CINP) 是一种治疗需求未得到满足的病症，影响着超过一半接受化疗的癌症患者。研究人员最近关注内源性大麻素系统，因为它在调节我们身体最重要的功能（包括疼痛）方面发挥着关键作用。我们使用体外和体内方法来确定合成大麻素 JWH-182 的毒性特征，以及它是否可能有效缓解 CINP。在体外，我们评估了 JWH-182 的一般毒性，测量了用不同浓度的化合物处理的成纤维细胞活力，及其对用紫杉醇处理的背根神经节神经元的神经保护作用。在体内，我们对小鼠的急性和 28 天重复剂量毒性进行了评估，并监测健康状况和完整的组织病理学检查。最后，我们使用特定的疼痛评估测试评估了 JWH-182 对 CINP 小鼠模型的功效。 JWH-182 在体外和体内研究中均具有可接受的毒性特征，并且能够显着降低小鼠 CINP 模型中的疼痛感知。然而，将这些结果转化为临床需要进一步调查。© 2024。作者。

Chemotherapy-induced neuropathic pain (CINP), a condition with unmet treatment needs, affects over half of cancer patients treated with chemotherapeutics. Researchers have recently focused on the endocannabinoid system because of its critical role in regulating our bodies' most important functions, including pain. We used in vitro and in vivo methods to determine the toxicity profile of a synthetic cannabinoid, JWH-182, and whether it could be potentially effective for CINP alleviation. In vitro, we evaluated JWH-182 general toxicity, measuring fibroblast viability treated with various concentrations of compound, and its neuroprotection on dorsal root ganglion neurons treated with paclitaxel. In vivo, we performed an evaluation of acute and 28-day repeated dose toxicity in mice, with monitoring of health status and a complete histopathological examination. Finally, we evaluated the efficacy of JWH-182 on a CINP model in mice using specific pain assessment tests. JWH-182 has an acceptable toxicity profile, in both, in vitro and in vivo studies and it was able to significantly reduce pain perception in a CINP model in mice. However, the translation of these results to the clinic needs further investigation.© 2024. The Author(s).